# Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.

> **NCT04352855** · — · UNKNOWN · sponsor: **Semmelweis University** · enrollment: 55 (actual)

## Conditions studied

- Ventilator Associated Pneumonia
- Antibiotic Resistant Infection

## Interventions

- **DRUG:** Ceftolozane/tazobactam

## Key facts

- **NCT ID:** NCT04352855
- **Lead sponsor:** Semmelweis University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-18
- **Primary completion:** 2020-05-19
- **Final completion:** 2020-05-19
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04352855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04352855, "Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04352855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*